Log in
NASDAQ:ALKS

Alkermes Competitors

$18.50
+0.07 (+0.38 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$18.33
Now: $18.50
$18.57
50-Day Range
$15.39
MA: $17.18
$18.43
52-Week Range
$11.98
Now: $18.50
$21.86
Volume286,244 shs
Average Volume1.56 million shs
Market Capitalization$2.94 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.18

Competitors

Alkermes (NASDAQ:ALKS) Vs. AMGN, GILD, VRTX, REGN, BIIB, and SGEN

Should you be buying ALKS stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Alkermes, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN).

Amgen (NASDAQ:AMGN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Insider and Institutional Ownership

71.7% of Amgen shares are held by institutional investors. Comparatively, 83.4% of Alkermes shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 4.5% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Amgen and Alkermes' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.60$7.84 billion$14.8215.17
Alkermes$1.17 billion2.51$-196,620,000.00$0.07264.29

Amgen has higher revenue and earnings than Alkermes. Amgen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amgen and Alkermes' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Alkermes-6.28%9.35%5.50%

Analyst Ratings

This is a summary of recent recommendations and price targets for Amgen and Alkermes, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1121502.50
Alkermes17202.10

Amgen currently has a consensus target price of $254.08, suggesting a potential upside of 13.02%. Alkermes has a consensus target price of $20.50, suggesting a potential upside of 10.81%. Given Amgen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Amgen is more favorable than Alkermes.

Volatility and Risk

Amgen has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Summary

Amgen beats Alkermes on 11 of the 14 factors compared between the two stocks.

Alkermes (NASDAQ:ALKS) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Insider and Institutional Ownership

83.4% of Alkermes shares are owned by institutional investors. Comparatively, 77.9% of Gilead Sciences shares are owned by institutional investors. 4.5% of Alkermes shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Alkermes and Gilead Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.17 billion2.51$-196,620,000.00$0.07264.29
Gilead Sciences$22.45 billion3.35$5.39 billion$6.149.78

Gilead Sciences has higher revenue and earnings than Alkermes. Gilead Sciences is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alkermes and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alkermes-6.28%9.35%5.50%
Gilead Sciences5.48%37.77%12.76%

Analyst Ratings

This is a breakdown of current recommendations for Alkermes and Gilead Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alkermes17202.10
Gilead Sciences2151002.30

Alkermes currently has a consensus price target of $20.50, suggesting a potential upside of 10.81%. Gilead Sciences has a consensus price target of $76.1538, suggesting a potential upside of 26.86%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Alkermes.

Volatility and Risk

Alkermes has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Summary

Gilead Sciences beats Alkermes on 11 of the 14 factors compared between the two stocks.

Alkermes (NASDAQ:ALKS) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Insider and Institutional Ownership

83.4% of Alkermes shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 4.5% of Alkermes shares are owned by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Alkermes and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.17 billion2.51$-196,620,000.00$0.07264.29
Vertex Pharmaceuticals$4.16 billion14.16$1.18 billion$4.2952.85

Vertex Pharmaceuticals has higher revenue and earnings than Alkermes. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alkermes and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alkermes-6.28%9.35%5.50%
Vertex Pharmaceuticals38.51%28.55%20.68%

Analyst Ratings

This is a breakdown of current recommendations for Alkermes and Vertex Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alkermes17202.10
Vertex Pharmaceuticals082212.77

Alkermes currently has a consensus price target of $20.50, suggesting a potential upside of 10.81%. Vertex Pharmaceuticals has a consensus price target of $290.5862, suggesting a potential upside of 28.18%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Alkermes.

Volatility and Risk

Alkermes has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Alkermes on 13 of the 15 factors compared between the two stocks.

Alkermes (NASDAQ:ALKS) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Insider and Institutional Ownership

83.4% of Alkermes shares are owned by institutional investors. Comparatively, 85.9% of Regeneron Pharmaceuticals shares are owned by institutional investors. 4.5% of Alkermes shares are owned by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Alkermes and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.17 billion2.51$-196,620,000.00$0.07264.29
Regeneron Pharmaceuticals$7.86 billion6.98$2.12 billion$21.4723.94

Regeneron Pharmaceuticals has higher revenue and earnings than Alkermes. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alkermes and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alkermes-6.28%9.35%5.50%
Regeneron Pharmaceuticals37.30%26.71%19.39%

Analyst Ratings

This is a breakdown of current recommendations for Alkermes and Regeneron Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alkermes17202.10
Regeneron Pharmaceuticals0101312.63

Alkermes currently has a consensus price target of $20.50, suggesting a potential upside of 10.81%. Regeneron Pharmaceuticals has a consensus price target of $628.52, suggesting a potential upside of 22.27%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Alkermes.

Volatility and Risk

Alkermes has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Alkermes on 14 of the 15 factors compared between the two stocks.

Alkermes (NASDAQ:ALKS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Volatility and Risk

Alkermes has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Insider and Institutional Ownership

83.4% of Alkermes shares are owned by institutional investors. Comparatively, 78.9% of Biogen shares are owned by institutional investors. 4.5% of Alkermes shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Alkermes and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alkermes-6.28%9.35%5.50%
Biogen35.63%51.00%23.54%

Analyst Ratings

This is a breakdown of current recommendations for Alkermes and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alkermes17202.10
Biogen5151302.24

Alkermes currently has a consensus price target of $20.50, suggesting a potential upside of 10.81%. Biogen has a consensus price target of $305.9032, suggesting a potential upside of 25.48%. Given Biogen's stronger consensus rating and higher possible upside, analysts clearly believe Biogen is more favorable than Alkermes.

Earnings and Valuation

This table compares Alkermes and Biogen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.17 billion2.51$-196,620,000.00$0.07264.29
Biogen$14.38 billion2.61$5.89 billion$33.577.26

Biogen has higher revenue and earnings than Alkermes. Biogen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Alkermes on 11 of the 14 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Risk and Volatility

Seagen has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.

Insider and Institutional Ownership

92.0% of Seagen shares are owned by institutional investors. Comparatively, 83.4% of Alkermes shares are owned by institutional investors. 31.1% of Seagen shares are owned by insiders. Comparatively, 4.5% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Seagen and Alkermes' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen-25.17%-18.32%-15.49%
Alkermes-6.28%9.35%5.50%

Analyst Recommendations

This is a summary of current ratings for Seagen and Alkermes, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen161112.63
Alkermes17202.10

Seagen currently has a consensus target price of $176.75, suggesting a potential upside of 4.51%. Alkermes has a consensus target price of $20.50, suggesting a potential upside of 10.81%. Given Alkermes' higher probable upside, analysts plainly believe Alkermes is more favorable than Seagen.

Valuation & Earnings

This table compares Seagen and Alkermes' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million33.26$-158,650,000.00($1.33)-127.16
Alkermes$1.17 billion2.51$-196,620,000.00$0.07264.29

Seagen has higher earnings, but lower revenue than Alkermes. Seagen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Summary

Alkermes beats Seagen on 8 of the 15 factors compared between the two stocks.


Alkermes Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$224.81+2.0%$130.88 billion$23.36 billion18.13Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.9$60.03+0.9%$75.25 billion$22.45 billion61.89Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$226.71+3.8%$58.95 billion$4.16 billion28.63
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.1$514.05+1.1%$54.85 billion$7.86 billion19.90
Biogen logo
BIIB
Biogen
2.0$243.78+0.8%$37.51 billion$14.38 billion8.07Analyst Revision
Seagen logo
SGEN
Seagen
1.4$169.12+2.2%$30.49 billion$916.71 million-112.00Analyst Downgrade
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.0$123.83+0.7%$27.10 billion$4.99 billion28.93
Incyte logo
INCY
Incyte
1.5$83.25+2.5%$18.23 billion$2.16 billion-53.03
Exact Sciences logo
EXAS
Exact Sciences
1.6$118.19+2.0%$17.78 billion$876.29 million-53.48
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$129.86+3.4%$15.09 billion$219.75 million-16.58Analyst Report
Analyst Revision
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.0$80.40+2.8%$14.60 billion$1.70 billion18.40
Repligen logo
RGEN
Repligen
1.4$186.99+3.0%$9.84 billion$270.24 million322.40
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$95.56+0.5%$8.93 billion$788.10 million45.29Analyst Downgrade
Novavax logo
NVAX
Novavax
1.8$125.69+18.4%$8.00 billion$18.66 million-45.71
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.8$51.13+1.7%$7.15 billion$1.12 billion106.52Insider Selling
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$23.24+2.1%$6.06 billion$182.24 million-20.21
United Therapeutics logo
UTHR
United Therapeutics
1.4$135.54+0.3%$6.02 billion$1.45 billion13.92
Exelixis logo
EXEL
Exelixis
1.9$19.41+3.5%$6.02 billion$967.78 million40.44Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.23+2.3%$5.44 billion$195.99 million251.44Analyst Report
Insider Selling
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$82.83+2.9%$4.39 billion$1.11 billion26.63
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$55.81+3.2%$3.86 billion$36.13 million-83.30
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90+0.6%$3.83 billion$806.43 million-9.33
OPKO Health logo
OPK
OPKO Health
1.9$4.13+4.4%$2.77 billion$901.90 million-12.51
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.3$11.83+1.7%$1.89 billion$428.41 million17.14
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.9$119.11+6.0%$1.84 billionN/A-10.76
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$10.12+3.5%$1.43 billion$102.43 million-12.19
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$85.92+1.7%$1.38 billion$120.28 million-86.79
Myriad Genetics logo
MYGN
Myriad Genetics
1.3$17.78+2.4%$1.34 billion$638.60 million-6.63
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$37.27+0.3%$1.23 billion$252 million-3.60
Innoviva logo
INVA
Innoviva
1.1$10.85+2.7%$1.10 billion$261.02 million5.54
Codexis logo
CDXS
Codexis
1.1$18.01+0.8%$1.07 billion$68.46 million-51.46
ImmunoGen logo
IMGN
ImmunoGen
1.7$5.52+4.0%$1.04 billion$82.27 million-12.84Analyst Upgrade
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.6$5.13+7.2%$905.78 million$48.83 million-6.75
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.4$22.75+4.4%$900.15 million$3.57 million-10.20
MannKind logo
MNKD
MannKind
0.9$3.08+4.2%$716.41 million$63.04 million-14.67
Agenus logo
AGEN
Agenus
1.6$3.71+5.4%$705.45 million$150.05 million-3.40
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$4.73+3.6%$690.21 million$109.33 million-3.88
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.2$12.41+2.4%$678.73 million$227.19 million5.94Analyst Downgrade
Heavy News Reporting
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.3$88.50+0.1%$650.03 million$38.19 million37.50
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$2.91+0.3%$623.59 million$150,000.00-4.16
Geron logo
GERN
Geron
1.4$1.87+3.2%$580.58 million$460,000.00-5.34
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$4.79+11.3%$527.73 million$35.22 million-3.50
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.11+5.8%$525.53 million$59.29 million-22.21
AMAG Pharmaceuticals logo
AMAG
AMAG Pharmaceuticals
0.8$13.75+0.0%$477.47 million$327.75 million-1.89
Molecular Templates logo
MTEM
Molecular Templates
1.6$9.12+3.1%$455.67 million$22.27 million-4.47
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$4.76+6.7%$420.40 million$143.01 million-0.91
XOMA logo
XOMA
XOMA
1.4$32.05+1.9%$353.26 million$18.37 million-28.87Analyst Report
Insider Selling
Verastem logo
VSTM
Verastem
1.5$1.99+14.6%$337.85 million$17.46 million-1.41High Trading Volume
Unusual Options Activity
Heavy News Reporting
PDL BioPharma logo
PDLI
PDL BioPharma
1.3$2.59+1.2%$295.85 million$54.76 million-1.95
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$2.77+5.8%$259.56 million$36.63 million-3.18
This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.